Who Paid My Doc
Vicente Benavidez
Physician Assistant, Medical Bakersfield, CA Physician Assistant
NPI 1356615421 CMS profile 10523356
2145 Niles St, Bakersfield, CA 93305
General payments
$13,312
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Vicente Benavidez of Bakersfield, CA is reported in the CMS Open Payments database as having received $13,312 across 664 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,389 | 130 | |
| 2024 | General | $3,441 | 136 | |
| 2023 | General | $2,518 | 123 | |
| 2022 | General | $2,496 | 136 | |
| 2021 | General | $2,469 | 139 |
Beside peers
- Vicente Benavidez
- Physician Assistant, Medical median
- Middle half of Physician Assistant, Medical
- National median
In program year 2025, general payments to Vicente Benavidez were reported at $2,389. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.
Show as a table
| Year | Vicente Benavidez | Physician Assistant, Medical median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $61 | $19–$193 | $163 |
| 2020 | $0 | $20 | $14–$64 | $114 |
| 2021 | $2,469 | $156 | $41–$563 | $132 |
| 2022 | $2,496 | $185 | $55–$649 | $149 |
| 2023 | $2,518 | $199 | $58–$717 | $160 |
| 2024 | $3,441 | $206 | $62–$740 | $164 |
| 2025 | $2,389 | $214 | $62–$755 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 121 drugsPart D claims
9,963
Drug cost
$1,538,234
Branded share of claims
34.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 263 | $241,591 | |
| Jardiance Empagliflozin | Brand | 235 | $136,604 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 165 | $109,022 | |
| Linzess Linaclotide | Brand | 197 | $102,084 | |
| Repatha Sureclick Evolocumab | Brand | 146 | $93,930 | |
| Rybelsus Semaglutide | Brand | 97 | $90,748 | |
| Prolia Denosumab | Brand | 56 | $89,232 | |
| Farxiga Dapagliflozin Propanediol | Brand | 133 | $75,076 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 115 | $61,497 | |
| Otezla Apremilast | Brand | 11 | $50,255 |
The 10 drugs with the highest cost, of 121 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 44 billing codesPaid by Medicare
$165,389
Medicare patients
251
Services billed
4,521
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 69% | |
| Diabetes | 62% | |
| Depression | 52% | |
| Ischemic heart disease | 42% | |
| COPD | 31% | |
| Osteoporosis | 29% | |
| Chronic kidney disease | 25% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 112 | 116 | $9,402 |
| Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 | Office | 33 | 33 | $4,316 |
| Pneumococcal conjugate vaccine, 15 valent (pcv15), for intramuscular use 90671 | Office | 15 | 15 | $3,727 |
| Pneumococcal vaccine for injection into muscle 90670 | Office | 12 | 12 | $3,034 |
| Influenza vaccine, trivalent derived from recombinant dna 90673 | Office | 12 | 12 | $982 |
| Influenza vaccine, trivalent, 0.5 ml dosage 90658 | Office | 11 | 11 | $236 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 70 | 355 | $233 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 65 | 298 | $97 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 27 | 170 | $74 |
| Injection, cefazolin sodium, 500 mg J0690 | Office | 16 | 31 | $14 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 40 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| REXULTI |
|
$222 | 13 | — |
| XIFAXAN |
|
$221 | — | — |
| Kerendia |
|
$216 | — | — |
| CAPLYTA |
|
$189 | 13 | — |
| AIRSUPRA |
|
$184 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 40 with PatronRecords
664 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physician Assistant, Medical in California
Nicola Lowrey
Physician Assistant, Medical · Orange, CA
Justin Love
Physician Assistant, Medical · Loma Linda, CA
Alison Gracom
Physician Assistant, Medical · Irvine, CA
Jeffrey Bonnaud
Physician Assistant, Medical · Los Angeles, CA
Ana Torres
Physician Assistant, Medical · Laguna Beach, CA
Heather Parlett
Physician Assistant, Medical · Redlands, CA
Related records
Physician Assistant, Medical in California
Practitioners in the same specialty and state, ranked by reported value.
All Physician Assistant, Medical
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.